ClinicalTrials.gg

Program

zelquistinel

Also written as “Zelquistinel” and “AGN-241751”.

Its studies are mostly in Depressive Disorder, Major, led by Syndeio Biosciences.

Furthest: phase 2, since Jun 22, 20185 company-led studies, 2 open or runningNext primary completion: Sep 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Syndeio Biosciences52 open or runningphase 2since Jun 22, 2018Jun 22, 2018Sep 2027phase 2 · NCT06547489

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 22, 2018First study: phase 2 study in Depressive Disorder, MajorFirst studyNCT03586427 · 251 enrolled · United States
  2. Oct 30, 2018Phase 2 study in Depressive Disorder, MajorNCT03726658 · 226 enrolled · United States
  3. Jul 18, 2021Phase 1 study in Depressive Disorder, MajorNCT04981561 · 68 enrolled
  4. Aug 7, 2024Phase 2 study in Depressive Disorder, MajorNCT06547489 · 164 planned · United States
  5. Aug 4, 2025Phase 2 study in Depressive Disorder, MajorNCT07115329 · 164 planned · United States

Ahead

  1. Sep 2027Primary completion: phase 2 study in Depressive Disorder, MajorNCT06547489
  2. Mar 30, 2028Primary completion: phase 2 study in Depressive Disorder, MajorNCT07115329

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07115329Depressive Disorder, Major · United States2RecruitingMar 30, 2028164
NCT06547489Depressive Disorder, Major · United States2RecruitingSep 2027164
NCT04981561Depressive Disorder, Major1CompletedDec 21, 201768
NCT03726658Depressive Disorder, Major · United States2CompletedOct 23, 2019226
NCT03586427Depressive Disorder, Major · United States2CompletedJul 22, 2019251

How it is read

Names in the registry

  • “Zelquistinel”, 2 entries
  • “AGN-241751”, 2 entries
  • “zelquistinel”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.